Tetra Bio-Pharma Confirms Regulatory Strategy of Lead Product CAUMZ™ and Strengthens Management Team

OTTAWA, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today confirmed its regulatory strategy of its CAUMZ^TM (PPP011) inhalation drug product and provided additional updates on its progress with U.S. Food and Drug Administration (FDA) for an expedited review. Additionally, the company provided updates on its plans and preparations for commercial launch of CAUMZ^TM, which include the appointments of key strategic personnel.

“Tetra’s regulatory team has made tremendous progress and we are pleased to confirm our regulatory strategy of CAUMZ^TM.  Our clinical development strategy to date has been aimed at addressing all of the requirements of the Food and Drug Act and obtaining FDA approval for CAUMZ^TM-Kit,” commented Dr. Guy Chamberland, CEO and Chief Regulatory Officer of Tetra Bio-Pharma Inc.  "To that end, we have taken the care to address all of the regulatory requirements in our Type B meeting with the FDA and look forward to providing additional clarity as we receive confirmation from the FDA on our final development plan.”

Dr. Chamberland continued, “As we prepare to continue our clinical development work based on the feedback from the FDA, we are also preparing for commercialization and launch of CAUMZ^TM.  This work requires we diligently prepare our manufacturing facilities, which includes scaling up to manufacture commercial batches of CAUMZ^TM and submitting commercial applications to the proper authorities in order to be ready to launch upon potential approval. As part of our strategic plan, we have added key personnel to important commercialization roles. I am pleased to welcome Dr. Melanie Kelly in the role of Chief Scientific Officer for Tetra.  Melanie brings tremendous experience and will be instrumental in helping develop CAUMZ^TM. Additionally, I am thrilled to announce Steeve Néron has assumed the role of Chief Operating Officer after formerly having served as Senior Vice President of Marketing and Medical Affairs for Tetra.”

“We are diligently preparing for commercialization, with the appointments of key personnel, preparations in our manufacturing capabilities and plans on the regulatory front.”  Mr. Chamberland concluded, “We look forward to additional updates as we continue to prepare for the launch of CAUMZ^TM.”

As part of its development strategy, Tetra initiated regulatory activities earlier this year to hold a Type B meeting with the FDA to request clarification on the nonclinical safety requirements for the submission of the marketing application (NDA) and supplemental marketing applications (sNDA), medical device requirements, eligibility for expedited review (i.e., fast track designation, breakthrough therapy designation, accelerated approval, or priority review designation) and marketing exclusivity for the drug and the Mighty Medic device.  The Company expects the Type B meeting to be completed by the end of December 2019, and will provide an update to the market on the outcome of this meeting.

Tetra believes once it gains approval of CAUMZ^TM in patients with advanced cancer pain, it will continue the clinical development program in parallel and seek approval in breakthrough pain and fibromyalgia. The Company believes these supplemental applications will build on the marketing exclusivity anticipated to be obtained for CAUMZ^TM-Kit and significantly expand the target market size.

Tetra is currently in the process of formalizing its strategy on manufacturing CAUMZ^TM for the global market. The Company will provide the market with updates as significant developments are achieved.  According to Dr. Chamberland, "Scale-up to commercial batch size is an important aspect for any pharmaceutical partner, and Tetra is already focusing efforts on manufacturing commercial batches of CAUMZ^TM to be able to submit the marketing applications and to be ready to launch the drug if approved."

Finally, Tetra announced that Dr. Melanie Kelly will join the team as Chief Scientific Officer. Dr. Kelly brings decades of experience in the fields of cannabinoid research and drug development. Additionally, the company is appointing Steeve Néron as Chief Operating Officer.  Mr. Néron has previously served as Senior Vice President of Marketing and Medical Affairs.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Investor Contact:
Bruce Mackle
LifeSci Advisors LLC
646-889-1200
[email protected] 

Media Contact:
Andrew Mielach
LifeSci Public Relations
646-876-5868
[email protected] 

Canada:
Carol Levine
Energi PR
514-288-8500 ext. 226
[email protected]